European Union

EPO Patent EP4494655A1: Multi-specific molecule and immune checkpoint inhibitor

The European Patent Office has published patent application EP4494655A1, titled 'Multi-specific molecule and immune checkpoint inhibitor,' filed by Daiichi Sankyo Company, Limited. The patent concerns novel therapeutic combinations for treating cancer.

EPO Patent: Composition for Controlling Bacterium Proliferation in Intestine

The European Patent Office has published patent application EP4494483A1 for a composition designed to control bacterium proliferation in the intestine. The patent, assigned to MEIJI CO., LTD, details specific uses and classifications related to pharmaceutical and food science applications.

EPO Patent EP4494637A1 on Coenzyme Q10 Crystal

The European Patent Office has published patent EP4494637A1, filed by Kaneka Corporation, concerning a solid composition containing a Form II-type crystal of reduced Coenzyme Q10. This patent is relevant to the pharmaceutical and food manufacturing sectors.

EPO Patent EP4493274A1 for Cariprazine Salts Depot Systems

The European Patent Office has published patent application EP4493274A1 for depot systems comprising cariprazine or salts thereof, filed by Mapi Pharma Ltd. The patent publication date is March 18, 2026.

Patent EP4507726A1: Arginine formulations with PD-1 antibody

Patent EP4507726A1: Arginine formulations with PD-1 antibody

Dimeric Compounds as Inhibitors of Glycogen Synthase 1 (Gys1)

The European Patent Office has published patent application EP4587118A1 for dimeric compounds that inhibit Glycogen Synthase 1 (Gys1). The application lists Maze Therapeutics, Inc. as the applicant and details various inventors. This publication relates to potential new therapeutic agents.

EPO Patent Publication: Anti-Folate Receptor Alpha Antibodies

The European Patent Office has published patent application EP4499697A1 concerning anti-folate receptor alpha antibodies and their methods of use. The application was filed by Zymeworks BC Inc. and lists multiple inventors. This publication is part of the standard patent application process.

EPO Patent Publication EP4630420A1 on NLRP3 Inhibitors

The European Patent Office has published patent application EP4630420A1 concerning inhibitors of NLRP3, with F. Hoffmann-La Roche AG listed as the applicant. This publication details potential new therapeutic compounds and their applications.

Velusetrag Patent for Chronic Intestinal Pseudo-Obstruction Treatment

The European Patent Office has published patent application EP4590303A1 for Alfasigma S.p.A. concerning the use of Velusetrag for treating chronic intestinal pseudo-obstruction. This patent is designated for multiple European states.

EPO Patent Application: Modulating KRAS(G12D) Compositions

The European Patent Office has published patent application EP2024044334A2 by Ranok Therapeutics (Hangzhou) Co. Ltd. concerning methods and compositions for modulating KRAS(G12D). The publication date is March 18, 2026.